NEW YORK, December 29, 2025, 05:56 ET — Premarket
- Regencell Bioscience shares were down 3.2% at $20.48 in premarket trading.
- The stock fell nearly 14% in the prior session, according to market data.
- Investors are watching for fresh updates after the company’s last press release in late October tied to its annual report filing.
Regencell Bioscience Holdings Limited shares fell 3.2% to $20.48 in premarket trading on Monday.
The Nasdaq-listed microcap ended the prior session down nearly 14% at $21.16, extending a streak of sharp swings.
The move matters now because investors have had little fresh company news to trade against. Regencell’s investor relations site shows its most recent press release was dated October 31.
That October release said Regencell filed its annual report on Form 20-F — an annual filing used by foreign private issuers — for the fiscal year ended June 30, 2025.
In that annual report, Regencell described itself as an early-stage developer focused on traditional Chinese medicine (TCM) for neurocognitive disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).
The same filing said the company has “no saleable products” and has not generated any revenue from product sales. It also reported net losses for fiscal 2025 and said it expects to continue to incur losses. SEC+1
Regencell’s 20-F also flagged that its ability to continue operating depends heavily on raising additional capital, and said management concluded there was “substantial doubt” about its ability to continue as a going concern within a year of the financial statements’ issuance. A “going concern” warning is an accounting term that signals a company may need more funding to keep operating. SEC
Corporate actions have also played a role in the stock’s history. A June filing said Regencell effected a 38-for-one forward stock split, paid as a stock bonus, after announcing the plan earlier in the month.
A forward stock split increases the number of shares outstanding while reducing the price per share, without changing the company’s overall market value on its own.
With no new release since late October, traders in the stock are likely to focus on whether Monday’s premarket weakness carries into the cash open, when liquidity typically improves.
Investors are also watching for any regulatory or clinical updates, since the company said it has not applied for regulatory approvals and has not generated revenue from product sales.
On the calendar, Nasdaq’s earnings page lists an estimated report date of January 30, 2026, though such dates can change and are not always company-confirmed.
For now, the stock’s next direction may hinge less on fundamentals and more on risk appetite and positioning, after last week’s sharp drop and another early slide before the bell.
